(Q57088775)
Statements
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study (English)
0 references
May 2014
0 references
50
0 references
8
0 references
1422-1429
0 references